India Hemangioblastoma Market

ID: MRFR/HC/54545-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026
India Hemangioblastoma Market Research Report By Tumor Site (Brain, Spinal Cord, Retina), By Diagnosis (CT Scan, MRI Scan, Others) and By Treatment (Surgery, Chemotherapy, Radiotherapy, Corticosteroids, Anticonvulsants, Others) - Growth & Industry Forecast 2025 To 2035
India Hemangioblastoma Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.83%
2024 Market Size$ 133.11 Million
2025 Market Size$ 143.53 Million
2035 Market Size$ 304.93 Million
Key Players
Novartis AG
Bristol-Myers Squibb Company
Roche Holding AG
Eli Lilly and Company
Merck & Co.
Inc.
Trends
  • Technological Advancements in Treatment
  • Increased Awareness and Diagnosis
  • Regulatory Changes and Market Access
Opportunities
  • Advancements in Surgical Techniques
  • Rising Incidence of Hemangioblastoma
  • Rising Patient Advocacy and Support Groups
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Tumor Site (USD Million)
      1. 4.1.1 Brain
      2. 4.1.2 Spinal Cord
      3. 4.1.3 Retina
    2. 4.2 Construction, BY Diagnosis (USD Million)
      1. 4.2.1 CT Scan
      2. 4.2.2 MRI Scan
      3. 4.2.3 Angiogram
    3. 4.3 Construction, BY Treatment (USD Million)
      1. 4.3.1 Surgery
      2. 4.3.2 Chemotherapy
      3. 4.3.3 Radiotherapy
      4. 4.3.4 Corticosteroids
      5. 4.3.5 Anticonvulsants
    4. 4.4 Construction, BY Radiotherapy (USD Million)
      1. 4.4.1 Conformal Radiotherapy
      2. 4.4.2 Intensity Modulated Radiotherapy (IMRT)
      3. 4.4.3 Stereotactic Radiotherapy
      4. 4.4.4 Radiosurgery
    5. 4.5 Construction, BY Corticosteroids (USD Million)
      1. 4.5.1 Hydrocortisone
      2. 4.5.2 Dexamethasone
      3. 4.5.3 Methylprednisolone
      4. 4.5.4 Prednisolone
    6. 4.6 Construction, BY Anticonvulsants (USD Million)
      1. 4.6.1 Carbamazepine
      2. 4.6.2 Lamotrigine
      3. 4.6.3 Levetiracetam
      4. 4.6.4 Phenytoin
      5. 4.6.5 Sodium Valproate
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis AG (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb Company (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche Holding AG (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Eli Lilly and Company (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co., Inc. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca PLC (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer Inc. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 INDIA MARKET ANALYSIS BY TUMOR SITE
    3. 6.3 INDIA MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 INDIA MARKET ANALYSIS BY TREATMENT
    5. 6.5 INDIA MARKET ANALYSIS BY RADIOTHERAPY
    6. 6.6 INDIA MARKET ANALYSIS BY CORTICOSTEROIDS
    7. 6.7 INDIA MARKET ANALYSIS BY ANTICONVULSANTS
    8. 6.8 KEY BUYING CRITERIA OF CONSTRUCTION
    9. 6.9 RESEARCH PROCESS OF MRFR
    10. 6.10 DRO ANALYSIS OF CONSTRUCTION
    11. 6.11 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    12. 6.12 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    13. 6.13 SUPPLY / VALUE CHAIN: CONSTRUCTION
    14. 6.14 CONSTRUCTION, BY TUMOR SITE, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY TUMOR SITE, 2024 TO 2035 (USD Million)
    16. 6.16 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    18. 6.18 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
    20. 6.20 CONSTRUCTION, BY RADIOTHERAPY, 2024 (% SHARE)
    21. 6.21 CONSTRUCTION, BY RADIOTHERAPY, 2024 TO 2035 (USD Million)
    22. 6.22 CONSTRUCTION, BY CORTICOSTEROIDS, 2024 (% SHARE)
    23. 6.23 CONSTRUCTION, BY CORTICOSTEROIDS, 2024 TO 2035 (USD Million)
    24. 6.24 CONSTRUCTION, BY ANTICONVULSANTS, 2024 (% SHARE)
    25. 6.25 CONSTRUCTION, BY ANTICONVULSANTS, 2024 TO 2035 (USD Million)
    26. 6.26 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TUMOR SITE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY RADIOTHERAPY, 2025-2035 (USD Million)
      5. 7.2.5 BY CORTICOSTEROIDS, 2025-2035 (USD Million)
      6. 7.2.6 BY ANTICONVULSANTS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

India Hemangioblastoma Market Segmentation

India Hemangioblastoma Market By Tumor Site (USD Million, 2025-2035)

  • Brain
  • Spinal Cord
  • Retina

India Hemangioblastoma Market By Diagnosis (USD Million, 2025-2035)

  • CT Scan
  • MRI Scan
  • Angiogram

India Hemangioblastoma Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Corticosteroids
  • Anticonvulsants

India Hemangioblastoma Market By Radiotherapy (USD Million, 2025-2035)

  • Conformal Radiotherapy
  • Intensity Modulated Radiotherapy (IMRT)
  • Stereotactic Radiotherapy
  • Radiosurgery

India Hemangioblastoma Market By Corticosteroids (USD Million, 2025-2035)

  • Hydrocortisone
  • Dexamethasone
  • Methylprednisolone
  • Prednisolone

India Hemangioblastoma Market By Anticonvulsants (USD Million, 2025-2035)

  • Carbamazepine
  • Lamotrigine
  • Levetiracetam
  • Phenytoin
  • Sodium Valproate

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.